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ABSTRACT

Patients with Acquired Immune Deficiency Syndrome (AIDS), AIDS-Related
Complex (ARC) and other high-risk individuals were evaluated for lymphocyte
subsets and serum levels of IgG, IgA, IgM, complement C3 and C4, B2-rnicroglobulin, circulating immune complexes and antibodies to HIV (1). Patients with other
immunologic diseases not related to AIDS and healthy individuals not at risk for
AIDS were also included in the study.

AIDS-related patients overall showed

significant (p < .05) relative and absolute decreases helper/inducer T cells, and
relative and absolute increases in suppressor/ cytotoxic T cells, resulting in dramatic
decreases in helper to suppressor ratios. Relative decreases in total T cells and
increases in B cells and natural killer (NK) cells were also observed in some AIDSrelated patients. Four patients not at risk for AIDS had borderline and possibly
false positive HIV antibody results.

Antibody levels in one of these patients

gradually changed to negative after a period of a few weeks. AIDS-related patients
overall were also found to have significant (p < .05) increases in serum levels of
imrnunoglobulins, B2-microglobulin, and circulating immune complexes. Significant
changes in serum levels of Complement C3 and C4 were not observed.
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LITERATURE REVIEW

The First Cases

The first cases of AIDS were recognized when epidemiologists at the Centers
for Disease Control (CDC) noticed the sudden appearance of certain previously rare
diseases outside of their normally affected populations. In June 1981, the CDC
reported the occurrence of Pneumocystis carinii pneumonia (PCP) in five previously
healthy, young homosexual men from Los Angeles (2). The following month, 26
cases of Kaposi's sarcoma (KS) were reported in young male homosexuals from New
York and San Francisco (3). Four of these patients also had PCP.
The occurrence of these diseases in patients without underlying 1IIlillune
deficiency was considered highly unusual. This prompted the CDC to suggest that
physicians be alert for KS, PCP and other opportunistic infections (001) associated
with immune deficiency in homosexual men (3). Seventy additional cases of KS and
PCP in persons without underlying disease were reported to the CDC over the next
two months (4).
The CDC subsequently documented the occurrence of unexplained, persistent,
generalized lymphadenopathy (PGL), also referred to as lymphadenopathy syndrome
(LAS), in homosexual males from several major metropolitan areas (5).

The

epiderniologic characteristics of these patients were similar to those of the previously
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described patients with PCP, KS and 001. Many of the patients with PCP, KS and
001 also had a previous history of lymphadenopathy. The findings of abnormal
T lymphocyte helper to suppressor ratios and poor reactivity to delayed hypersensitivity skin-testing provided evidence of cellular immune dysfunction in some of the
LAS patients (5).
Further investigation by the CDC provided epidemiologic data which
indicated that the syndrome was occurring in populations other than male homosexuals.

Of 355 cases reported to the CDC through May 1982, 41 (12%) were

heterosexual men and 13 (4%) were heterosexual women (6). These heterosexual
patients were more likely to have used intravenous (IV) drugs than homosexuals
with the syndrome. Cases of the syndrome were also diagnosed in 34 Haitians living
in the United States (7) and in three patients with hemophilia A (8).
The CDC published a case definition of the new syndrome in September 1982
and called it the Acquired Immune Deficiency Syndrome (AIDS) (9). This report
documented the rapidly increasing incidence and high mortality rates for the
syndrome. The CDC recognized that the narrow case definition might not include
the entire spectrum of the AIDS epidemic. A definition was needed, however, for
monitoring the incidence of the disease since a specific test for diagnosis was not
available.
The CDC separated the reported cases of AIDS into the following groups
based upon risk factors: homosexual or bisexual males (75%), IV drug abu~ers
(13%), Haitians (6%), and hemophiliacs (0.3%) (9). Five percent of the cases could
not be placed into these groups. In subsequent reports, the CDC hypothesized that
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the disease was caused by a transmissible agent which was spread either by direct,
intimate contact with mucosal surfaces, or parenterally through contaminated blood
products (10).

Etiology
Researchers at the Pasteur Institute in France published the first report of a
new retrovirus isolated from the lymph node of a patient with LAS (11). They later
called the new virus lymphadenopathy-associated virus (LAV).

Two groups of

researchers in the United States also found evidence of retroviruses in tissues of
patients with AIDS and AIDS-related complex (ARC) (12,13,14). These viruses
were found to be different from two other previously known human retroviruses,
human T-lymphotropic viruses (HTLV) types I and II. The U.S. investigators called
the new virus HTLV-III.
The new virus isolates were initially difficult to grow in tissue culture because
the cells were so easily killed by the virus; however, several cell lines of leukemic
T cells which resisted being killed were eventually found. These cell lines allowed
the production of the large amounts of virus necessary for the development of
specific antisera needed to characterize the new viruses. These infected cell lines
were also used as a source of viral proteins for the production of a commercial
blood test (15).
Subsequent evidence showed that the viruses isol.ated independently in_France
and the United States were different strains of the same virus (16,17). The viruses
had the same morphology when examined by electron microscopy, they were
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cytopathic to helper/inducer T lymphocytes, and major differences were not detected
using serologic methods.
Additional evidence supported the hypothesis that the new retrovirus was the
etiologic agent of AIDS. There was a very high prevalence of antibody to HTLVIII in the blood of patients with AIDS or ARC (18). Almost no healthy individuals
outside of the high-risk groups were found to have these antibodies. Furthermore,
a high prevalence of HTLV-ill antibodies in asymptomatic members of the highrisk groups suggested that the clinical spectrum of HTLV-III infection was wider
than the AJDS and ARC syndromes (18).
A new name designed to conform to international standards of nomenclature
for viruses was recently proposed for the AIDS virus: the Human Immunodeficiency
Virus (HIV). The U.S. Public Health Service has recently recommended that this
new name be adopted exclusively throughout the world in order to reduce confusion
about the various names for the AIDS virus.
Like all retroviruses, HIV contains RNA as its genetic material (15). HIV
RNA, once inside a host cell, is transcribed into a complimentary strand of DNA by
a reverse transcriptase enzyme carried by the virus.

This "proviral" DNA then

travels to the nucleus of the host cell, where it is incorporated into the host DNA.
The provirus may remain dormant in the host nucleus until becoming activated by
certain events which are not yet well understood.
The primary host cell of HIV is a T lymphocyte of the helper/inducer
phenotype (15). The virus recognizes a specific receptor on the surface of the host
cell.

Once the virus is attached to its receptor, it is brought into the cell by a
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process known as "receptor-mediated endocytosis." Studies have shown that the
receptor for the virus is probably the same antigen which reacts with the OKT4 and
Leu-3 monoclonal antibodies used to identify helper/inducer T cells (16).
The normal response of the lymphocyte to a secondary infection may be a
stimulus for the activation of the provirus.

Upon activation, large numbers of

progeny viruses are produced quickly. The progeny viruses leave the host cell by
budding from the plasma membrane, which apparently causes the lysis and death of
the cell.
The HIV virus is a spherical particle, approximately 100 Angstroms in
diameter (15). The structure of the virus consists of nucleic acid surrounded by a
protein core and an envelope. Several copies of the reverse transcriptase enzyme
are also carried within the core. There are two core proteins, designated p18 and
p24.
The envelope is a lipid bilayer derived from the plasma membrane of the
host cell (15).

Envelope glycoproteins are made up of two major components:

gp41, an integral membrane protein and gp 120, an external protein. The gp 120
component is probably involved in the attachment of the virus to its receptor on the
host cell. Gp 120 is also probably involved in the process of budding from the host
cell. A significant amount of genetic variability between different strains of the virus
has been noted in the gp 120 protein.
The genetics of the HIV virus are more complex than those of any other
retrovirus studied (15). As with other retroviruses, there are three major genes
which code for structural proteins: the env gene codes for the envelope proteins, the

6

gag gene codes for the core proteins, and the pol gene codes for the reverse
transcriptase enzyme. There are at least four additional genes whose products
appear to be involved in the strict regulation of gene expression and activation of
the provirus from its resting stage.
One of the most intriguing aspects of the HIV virus is its origin. There is no
question that AIDS is a new disease, at least in the United States and Europe (15).
The earliest evidence of HIV infection in humans is the presence of antibodies in
sera from the 1950's in central Africa.
A virus related to HIV, designated simian T-lymphotropic virus ill (S1LVIII), has been isolated from African green monkeys in central Africa (15). Although
S1LV-III does not cause immune deficiency in its normal host and is not closely
related genetically to HIV, several viruses which appear to be intermediates between
S1LV-III and HIV have been recently isolated. One hypothesis is that S1LV-III
somehow infected humans and underwent a series of mutations which resulted in
HIV. The infection is believed to have spread from Africa to the Caribbean and
then to the United States and Europe.

Epidemiology
The epidemiologic evidence indicates that transmission of the HIV virus
occurs through sexual, parenteral or perinatal exposure. The primary modes of
transmission are through semen, blood and blood products. Transmission by casual
exposure or other indirect means has not been substantiated.
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Sexual Transmission. The high incidence of AIDS and HIV infection in

homosexual males has been associated with certain elements of the homosexual
lifestyle. The most important factor appears to be a history of sexual contact with
a large number of male partners (19), which presumably increases the chances of
having sex with an infected individual.
Heterosexual transmission has been documented from male to female
(20,21,22,23) as well as from female to male (23,24,25). The ratio (1.1 to 1) of male
to female patients with AIDS in Africa, where AIDS is considered a heterosexual
disease, suggests that the frequency of transmission from female to male is
approximately the same as from male to female (26). The method of intercourse
(vaginal, oral or rectal) does not appear to be an important factor in heterosexual
transmission (23).
Infectious virus has been found in lymphocytes isolated from the semen of
infected individuals (27,28). This finding might provide an explanation for male to
male and male to female transmission. The mode of female to male transmission
is unclear however, since the presence of virus and/or virus-infected cells in female
vaginal secretions has not been reported (23).
Parenteral Transmission. Parenteral transmission has been shown to occur

through blood transfusions, the use of contaminated needles and accidental
needlestick injuries.
Studies of parenteral drug users suggest that the risk of HIV transmission is
related to the f!equency of parenteral exposure (25). This finding is consistent with
an observed low rate of infectivity from isolated exposures.
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A variety of blood components have been identified as transmitting the virus
from high-risk donors, including red cells, platelets, plasma and whole blood (29).
Because the HIV virus lyses the lymphocytes it infects, the virus can be present in
and transmitted through cell-free blood products as well as cell-containing products
(30).

The virus has also been shown to be transmitted by Factor VIII, a life-saving
blood clotting factor taken regularly by patients with hemophilia A. There are two
preparations of Factor VIII: lyophilized concentrate and cryoprecipitate. Lyophilized
concentrate is prepared from pooled plasma originating from two- to five-thousand
donors. Cryoprecipitate is prepared from the plasma of individual donors. Patients
who receive lyophilized concentrate appear to be at higher risk of being infected
with HIV than those who receive cryoprecipitate (31).

Since the lyophilized

concentrate originates from the pooled plasma of a large number of donors, there
is presumably a higher probability that an individual lot will be contaminated with
the virus.
The number of new cases of AIDS acquired from blood products is expected
to decline due to measures taken by the nation's blood banks to reduce the number
of contaminated products.

High-risk individuals have been discouraged from

donating blood since March 1983 (32), and there is evidence that the number of
homosexuals who have donated blood has decreased (29). All blood donated since
March 1985 has been screened for antibodies to the I-UV virus. Positive donations
have been eliminated from the blood supply and donors who tested positive have
been prohibited from donating blood in the future.
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Isolated cases of HIV transmission to health care workers via accidental
needlestick have been reported (25,33).

A number of studies have suggested

however that the risk of this type of transmission is very low (25,34-37), even when
the needles have been contaminated by blood from AIDS patients (38,39).
Perinatal Transmission. Transmission of HIV infection from mother to

infant can occur during either the prenatal or postnatal periods (40-43). Two cases
involving infants who had no contact with their mothers after birth support the
possibility of prenatal transmission (44,45). Since one of these infants was delivered
by cesarean section, the transmission probably occurred across the placenta in utero.
Transmission through cervical secretions during labor and delivery has not been
verified.
Postnatal transmission has been implicated for an infant whose mother
acquired the infection from a postpartum blood transfusion (46). Since this infant
was breast-fed for 6 weeks, colostrum was suggested as the possible mode of
transmission. The possibility of this mode of transmission has been supported by the
isolation of HIV virus from the breast milk of infected women (47).
Public fears that AIDS might be spread by casual contact have not been
substantiated (48). A growing body of evidence supports the idea that intimate
sexual contact or direct transfer of significant amounts of blood are necessary for
infection to occur. Although the HIV virus has been detected in saliva (49), there
is no evidence that the disease can be transmitted by saliva.

Furthermore, the

currently available evidence does not support transmission by aerosols (50), insect
bites (48), routine social contact or even close household contact (22).
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The HIV virus is very labile when left out in the environment and it is not
believed to be readily transmissible (50,51). The virus is easily killed by many
disinfectants, such as 40% ethanol, 1% Lysol, 5% phenol, 1:10 dilution of sodium
hypochlorite household bleach, isopropyl alcohol, NP-40 and 3% hydrogen peroxide
(52). The virus has also been found to be very susceptible to extremes in pH and
temperature (52).

Recent epidemiologic data suggest that standard procedures

currently employed in hospital settings, such as the use of halogenated soaps and
alcohol, appear to be adequate for prevention of transmission of the HIV virus (53).
High-Risk Groups. Based upon epidemiologic data, the groups presently

recognized as high-risk for exposure to HIV are: 1) homosexual and bisexual men
with multiple sex partners, 2) abusers of intravenous drugs who share needles, 3)
hemophiliacs who receive Factor VIII, 4) sexual partners of high-risk individuals, and
5) infants born to high-risk mothers.
In the early days of the epidemic, Haitians with no known risk factors were

placed into a separate risk group. However, initial investigators were apparently
mislead by strict cultural taboos which kept many Haitian patients from admitting
to homosexual activity and drug abuse (54). The CDC decided that a classification
based on national origin alone was not consistent with what was known about the
transmission of the disease and that such a classification unfairly stigmatized Haitian
immigrants. Therefore, Haitians with AIDS were placed into a general category
whose members had no known risk factors. The CDC subsequently decided that
this classification was also misleading after studies showed that the majority of AIDS
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cases in Haitians and recent immigrants from central Africa could be attributed to
heterosexual transmission (48).

Clinical Aspects
AIDS. The original CDC surveillance definition of AIDS was: "a disease at

least moderately predictive of a defect in cell-mediated immunity, occurring in a
person with no known cause for diminished resistance to that disease. Such diseases
include KS, PCP, and serious other opportunistic infections (OOI)." (9)
The OOl's diagnostic for AIDS were specified as: "pneumonia, meningitis, or
encephalitis due to one or more of the following: aspergillosis, candidiasis,
cryptococcosis, cytomegalovirus (CMV), nocardiosis, strongyloidosis, toxoplasmosis,
zygomycosis, or atypical mycobacteriosis (species other than tuberculosis or leprae);
esophagitis due to candidiasis, CMV or herpes simplex virus (HSV); progressive
multifocal leukoencephalopathy; chronic enterocolitis (more than 4 weeks) due to
cryptosporidiosis; or unusually extensive mucocutaneous HSV infection of more than
5 weeks duration." (9)
AIDS can be ruled out in patients with other known causes of immune
deficiency: patients undergoing systemic corticosteroid or other immunosuppressive
or cytotoxic therapy; patients with widely spread cancer of lymphoid or histiocytic
tissue (lymphoma, Hodgkin's disease, lymphocytic leukemia, or multiple myeloma);
patients over 60 years of age (with regard to KS); patients under 28 days of age
(with regard to toxoplasmosis, HSV or CMV infection); or patients with an immune
deficiency caused by a genetic or developmental defect (9).
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The strict CDC definition of AIDS was designed to clearly separate AIDS
from other disease processes which might be reported due to increased awareness
of immune deficiencies by the medical community. The CDC later amended the
surveillance definition to allow the exclusion from an AIDS diagnosis those patients
who 1) have a normal helper to suppressor ratio and/ or a normal number of
helper/inducer T lymphocytes and 2) do not have detectable antibody to HIV (55).
Kaposi's Sarcoma. KS is a neoplasm characterized by single or multiple

vascular lesions on the skin, mucosa and/or visceral organs (56). The malignant
progenitor cell is uncertain, although it is probably either a vascular endothelial cell
or a pluripotential mesenchymal cell (57).
There are now three epidemiologic forms of KS: classical, African and
epidemic. Classical KS in the United States appears typically in men of Jewish or
Italian decent over the age of 60 (58). This form is usually localized and indolent
and responds well to radio- and chemotherapy (56,59). African KS is endemic in
equatorial Africa, where the disease comprises up to 10% of all neoplasms (57).
This form affects a younger population and is usually more progressive than classical
KS (56).
Epidemic KS, the form seen in patients with AIDS, is usually very malignant
and can be rapidly fatal (56). In this form, involvement of the lymph nodes and
gastrointestinal tract are common (59). Treatment of epidemic KS has been less
successful than for classical KS (59). The two-year survival rate for patients with
epidemic KS h~ been estimated to be less than 25%, whereas patients with classical
KS have survival periods of up to 13 years (58). KS has been seen in 34% of all
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AIDS patients and 92% of AIDS patients with KS have been homosexual males
(56).

A number of factors may be responsible for the presence of KS in patients
with AIDS: pre-existing immune deficiency, genetic factors and CMV infection.
Classical KS occurs more commonly in patients who are immunosuppressed: cancer
patients, transplant recipients and patients receiving immunosuppressive therapy
(58). Sixty percent of patients with KS in the United States possess the HLA-DR5
allele, as opposed to only 23% in the normal male homosexual population (59).
CMV antigen and DNA have been found in KS tissue (60). Furthermore, in the
hemophiliac population where exposure to CMV is low, the incidence of KS with
AIDS is low or non-existent.
AIDS patients with KS alone generally have higher numbers of helper/inducer T cells than those initially presenting with life-threatening opportunistic
infections. These patients appear to have a longer life expectancy, possibly because
they are presenting earlier in the course of a progressive immune deficiency (61).
Pneumocystis carinii Pneumonia.

Pneumocystis carinii is a ubiquitous

protozoan spread by the respiratory route. This microorganism causes disease only
when there is a deficiency in cell-mediated or humoral immunity (62). PCP is a
pulmonary disease which previously occurred mainly in young children and only
rarely in immunosuppressed adults (63). PCP is the most common 001 found in
patients with AIDS (62).
PCP may be insidious, characterized as dyspnea with or without a nonproductive cough and fever, or the disease may be fulminant (62). Symptoms can
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develop rapidly over several days or slowly over weeks or months. A chest X-ray
may show diffuse bilateral infiltrates, but the demonstration of organisms in
bronchial secretions or lung tissue by bronchial lavage or biopsy is important for
definitive diagnosis and the proper choice of therapy (62). Patients treated with
antibiotics usually respond very slowly, and at least 10% who survive the first
infection have recurrences.
AIDS-Related Complex. The term ARC has been used for patients who have

some type of otherwise unexplained immunologic abnormality, but do not have any
of the common secondary conditions listed by the CDC surveillance definition of
AIDS. These patients generally have at least LAS. LAS has been defined as
lymphadenopathy of at least 3-months duration involving two or more extrainguinal
sites, in the absence of any current illness or drug use known to cause lymphadenopathy (64). LAS and ARC may represent prodromal forms of AIDS (64).
Most AIDS-related patients are also noted to have certain constitutional
symptoms; including fatigue, fever, night sweats, diarrhea, weight loss of more than
5 pounds, and hepatomegaly and/or splenomegaly (5). These prodromal conditions
may occur for weeks, months or years before an AIDS-specific condition is noted.
Some patients have LAS for months or years with or without other constitutional
symptoms.
Asymptomatic Carriers. The majority of HIV seropositive individuals are

currently asymptomatic or only mildly symptomatic. The virus has been cultured
from many seropositive individuals (19,31,60), as well as some seronegative
individuals (22,65). Clearly, the latter individuals are a serious threat as blood
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donors, smce they would not be detected by the current antibody screening
procedures.
Treatment and Prognosis. There is no known cure for AIDS, ARC, or HIV

infection in general. At present, the primary focus of treatment is to control the
secondary conditions as they develop. Often, the physician must treat secondary
infections and tumors as they occur until ultimately an untreatable condition occurs.
This usually occurs within 18-24 months after an initial 001, or 24-48 months after
an initial KS lesion (62).
A wide variety of other modes of treatment are currently under investigation.
The most promising appear to be those which are aimed at preventing retroviral
replication: azidothymidine (AZT), suramin, ribavirin and a-interferon. However,
these drugs often have severe side effects. Many of these drugs inhibit replication
of the host cells, particularly those of the immune system, as well as the replication
of the virus (62). Preliminary clinical trials of AZT have showed such dramatic
benefits in some patients that the FDA has allowed widespread distribution of the
drug before the tests have been completed (62).
Other methods of treatment have been aimed at non-specifically stimulating
the immune system: dinitrochlorobenzene (DNCB), interferon, interleukin-2, transfer
factor, bone marrow transplantation, and plasmapheresis (62).
Due to the genetic variability of the envelope glycoproteins between strains
of the HIV virus, the development of an effective vaccine has been estimated to be
at least fives years away (62). Recent evidence that infection with some strains of
HIV might protect a patient from co-infection with distantly-related strains provides
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hope that a synthetic vaccine may be able to inhibit co-infection with the natural
virus in a similar manner (15).

The Cellular Immune System

The function of the immune system is to recognize foreign substances and
eliminate them from the body.

There are two definitive characteristics of an

immune response: 1) specificity for a particular foreign material (antigen), and 2)
memory of an antigen, such that future encounters provoke a quicker and more
powerful immune response.

The immune system can be subdivided into two

interrelated mechanisms: humoral immunity and cellular immunity.
Humoral immunity is mediated by proteins (antibodies) which have specificity
for a particular antigen. Specific antibody can neutralize an antigen in a number of
ways. Antibody may prevent a microorganism from attaching to a target tissue by
blocking the organism's receptor for the tissue. An antigen-antibody complex may
activate the complement system - a series of enzymatic reactions which ultimately
causes the lysis of the antibody-coated cell. Antibody may also enhance recognition
of an antigen by the cellular immune system.
Although most immune responses involve interaction between both humoral
and cellular immune mechanisms, cellular immunity is especially important in
eliminating the body's own cells which have been altered by cancer or by infection
with viruses.

Cellular immunity is mediated by white blood cells (leukocytes),

primarily macrophages and lymphocytes.
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Macrophages are motile cells which are present in most tissues throughout
the body, including peripheral blood, where they are called monocytes. They engulf
(phagocytize) and digest foreign particles, infected cells and cancerous cells.
Macrophages are referred to as "antigen-presenting cells" because after phagocytosis,
partially digested antigens are displayed on the surface of the macrophage so that
they can be recognized by lymphocytes.
Lymphocytes are present in peripheral blood, connective tissues and lymphoid
tissues. Three major functional subpopulations of lymphocytes can be distinguished:
T cells, B cells and natural killer (NK) cells.
B cells are the effectors of humoral immunity: upon stimulation they mature
into antibody-secreting plasma cells. Each B cell displays surface immunoglobulin
(slg) which is specific for a certain antigen. B cell slg is capable of recognizing
soluble antigen, as well as antigen which is bound to the surface of a cell.
T cells are lymphocytes which have matured in the thymus gland. Mature
T cells can be further subdivided into functionally distinct subpopulations: helper
T cells, inducer T cells, cytotoxic T cells and suppressor T cells.
Helper T cells have two basic functions: 1) they provide signals to allow
B cells to mature into antibody-producing cells, and 2) they provide signals to allow
cytotoxic T cells to carry out their functions (described below). Once the helper
functions have been provided, inducer T cells stimulate clonal expansion of B cells
and cytotoxic T cells into activated functional cells.
Cytoto~c T cells are the effectors of cellular immunity: they destroy specific
antigen-bearing cells by disrupting the membrane integrity of the target cells.
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Suppressor T cells have functions opposite to those of helper T cells: they
suppress the differentiation of B cells into antibody-secreting cells, and they suppress
the activity of cytotoxic T cells. Thus, together the helper and suppressor functions
provide homeostatic control of both the humoral and cellular immune responses.
Analogous to the slg of B cells, T cells also have receptors for a specific
antigen.

The aforementioned interactions between T cells, B cells and antigen

presenting cells involve specificity for a particular antigen. Most of these interactions also require specificity for certain types of major histocompatibility (MHC)
proteins.
MHC proteins are alloantigens; that is, they vary among genetically dissimilar
individuals of a species. In humans, MHC proteins are called human leukocyte
antigens (HlA). There are two main classes of human MHC proteins: class I
antigens (HlA types A, B and C) which are present on all nucleated cells, and class
II antigens (HlA types DR, DP and DQ) which are present mainly on antigenpresenting cells and B cells.
Helper and inducer T cells require the presence of class II MHC proteins for
the recognition of antigen presented by antigen-presenting cells. Suppressor and
cytotoxic T cells require the presence of specific antigen and class I MHC proteins
for the recognition of their target cells.
Like cytotoxic T cells, NK cells also bring about the lysis of virus-infected or
tumor cells. NK cells, however, apparently do not require recognition of specific
antigen or class I MHC proteins.
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The HIV virus has been shown to be cytopathic to T cells of the helper/inducer phenotype (16,17). The defects in cellular immunity observed in AIDS
patients are thought to result primarily from the loss of functions carried out by
helper and inducer T cells. In addition, the virus may exploit the mechanisms of
the cellular immune response in other ways to further depress cell-mediated
immunity.
Investigators have found a soluble suppressor factor that is secreted by HIV
infected cells (64,66). This factor blocks T cell-dependent immune responses, such
as the production of specific antibody and the proliferation of other T cells.
Disruption of antigen recognition may be another way the AIDS virus disrupts
the immune response (64). The virus may code for an altered Class I MHC protein,
thus preventing the recognition of the infected cell by the cytotoxic T cell. The virus
may also alter the infected cell's receptor for MHC Class II protein, which is
necessary for recognition of an antigen-presenting cell. Another possible mechanism
is that the virus may cause an infected cell to display reduced amounts of Class II
antigens, so that the cell cannot be recognized by helper and inducer T cells.

Laboratory Analysis of the Immune System

Lymphocyte Subpopulations. Lymphocyte subpopulations can be quantitated

through the use of fluorescently-labelled monoclonal antibodies which are directed
against cell surface markers. These markers represent differentiation antigens which
are present on functionally distinct types of lymphocytes (67).
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T cells can be identified by the presence of the CD3 marker. The CD3
marker is an integral membrane glycoprotein made up or three subunits (68).
Although it's function is unknown, CD3 is believed to be physically associated with
the T cell receptor for antigen. OKT3 and anti-Leu-4 are monoclonal antibodies
directed against the CD3 marker.
Helper and inducer T cells express the CD4 marker. Cells identified by this
marker are called "helper /inducer" T cells since the marker is present on both
helper T cells and inducer T cells. The CD4 marker is believed to play a role in the
recognition of class II MHC proteins (68). OKT4 and anti-Leu-3 are monoclonal
antibodies directed against the CD4 marker.
Suppressor and cytotoxic T cells express the CDS marker. Cells identified by
this marker are called "suppressor/ cytotoxic" T cells since the marker is present on
both suppressor T cells and cytotoxic T cells. However, subpopulations of NK cells
have also been found to express the CDS marker (69,70). The CDS marker is
believed to play a role in the recognition of class I MHC proteins (68). OKTS and
anti-Leu-2 are monoclonal antibodies directed against the CDS marker.
The ratio of the number of helper/inducer T cells (CD4+) to the number of
suppressor/cytotoxic T cells (CDS+) is referred to as the "helper to suppressor ratio."
The fluorescent-antibody technique for the enumeration of lymphocyte
subpopulations has only recently been introduced into clinical laboratories.
Therefore, the clinical significance of changes in these populations has not been well
characterized. A number of laboratories have reported a dramatic decrease in
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helper/inducer T cells and in helper to suppressor ratios found in AIDS-related
patients (71).
Serum Immunoglobulin Levels. Serum levels of immunoglobulins IgG, IgA

and IgM have been used to detect abnormalities in humoral immunity (72).
Decreased levels of serum immunoglobulins may suggest humoral immune deficiency
as the cause of recurrent infections. Hyperimmunoglobulinemia may be monoclonal,
as seen in malignancies of antibody-producing cell lines, or polyclonal as seen in
infections, liver disease, pulmonary disorders and autoimmune disorders.
Serum Complement Levels. The serum complement system consists of 11

components which react in sequence, resulting in increased vascular permeability,
attraction of polymorphonuclear leukocytes, adherence of complement-coated
immune complexes, enhancement of phagocytosis and changes in cell membranes
that lead to cell lysis and death. Increased levels of complement components C3
and C4 are associated with a variety of inflammatory and necrotic disorders as part
of the acute phase of the plasma protein response. Decreased levels of C3 and C4
are associated with chronic conditions in which total hemolytic complement activity
is reduced. Decreased levels of C4 are associated with activation of the classical
pathway. Decreased levels of C3 with normal levels of C4 indicate activation of the
alternative pathway (73).
Serum 6 2-Microglobulin Levels.

Human B2-microglobulin is a small

molecular weight protein present on all nucleated cells as the constant subunit of the
class I MHC antigens. This protein is released into the body fluids as the result of
cell turnover.

The rate of production of B2-microglobulin is increased in some

22
immunologic, malignant and viral diseases. In some cases, increased serum levels
have been correlated with high degrees of disease activity (74 ).
Circulating Immune Complexes. Immune complexes are large aggregates of

antigen and specific antibody. If the antibody is IgG or IgM, these complexes will
typically bind the Clq component of complement. Clq immune complexes can
activate the classical pathway of complement activation. High values are found in
a wide variety of chronic inflammatory and autoimmune diseases (75).
Antibodies to HIV.

The primary use of this test is to screen blood and

plasma donations so that antibody-containing products can be eliminated from the
blood supply. The presence of antibody to HN indicates past exposure to the virus.
A positive test is not a diagnosis of AIDS and a negative result does not exclude the
possibility of exposure to or infection with HIV (76).
The observed prevalence of antibody to HIV in the United States ranges
from less than 0.01 % in female blood donors to as high as 74% in men with
hemophilia (77-79). Among heterosexual IV drug abusers, the observed prevalence
of HIV infection has been measured from 2% to 59% in various geographic areas
(80,81). Observed seroprevalence among the heterosexual partners of persons at
increased risk for AIDS has varied from 10% in asymptomatic, seropositive
hemophilia patients to 71 % in the female partners of men with AIDS or ARC
(22,82,83). The observed HIV antibody prevalence among prostitutes varies from
5% to 40%, depending upon geographic area, but most of the seropositive women
also have histories of IV drug abuse (84 ).
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HIV has been isolated from 67% to 95% of persons with specific antibody
(25,85). Because infection has been demonstrated in asymptomatic persons, the
presence of specific antibody should be considered presumptive evidence of current
infection and infectiousness (77). However, detectable antibodies to HIV might not
develop until 2 - 4 months after exposure (77).

INTRODUCTION

AIDS is a relatively new immunologic disease caused by a recently isolated
and partially characterized retrovirus, the Human Immunodeficiency Virus (HIV).
Because AIDS is such a serious threat to the public health, an enormous amount of
AIDS research has been done in the 7 years since the disease was first recognized.
A diagnosis of AIDS is currently based primarily on clinical information, and there
is no single laboratory test available to confirm a diagnosis of AIDS. Due to the
wide spectrum of HIV infection, ranging from the asymptomatic carrier state to fullblown AIDS, it is important for the physician to be able to differentiate between the
various phases of AIDS and distinguish the disease from other immunologic
disorders.
This study was designed to investigate several laboratory parameters which
are commonly measured in AIDS-related patients. Patterns in the data were sought
which might aid in clinical diagnosis, disease staging and a better understanding of
the pathogenesis of the disease.

The problem of false-positive tests for HIV

antibodies in patients not at risk for AIDS was also investigated.
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MATERIALS AND METHODS

Patient Classification

The patients in this study bad been referred to the Allergy-Immunology Lab
of Central Florida, Inc. for lymphocyte subset analysis and/or HIV antibody testing.
Patients came from a variety of sources throughout the Central Florida area: local
hospitals, private physicians, other commercial laboratories, the Orange County
Health Department, and the Central Florida Blood Bank. Patients with other types
of immunologic disorders not related to AIDS and normal control subjects were also
included in the study.
After clinical evaluation and initial laboratory testing, patients were classified
into one of six groups: patients with a diagnosis of AIDS (Group 1), patients with
ARC or LAS (Group 2), other patients with possible AIDS-related conditions
(Group 3), patients with a possible false-positive HIV antibody test (Group 4),
patients with other immunologic disorders not related to AIDS (Group 5), and
healthy individuals who volunteered for the study (Group 6).
Group 3 included members of high-risk groups for AIDS, patients who
possibly had been exposed to HIV-infected individuals or patients who bad been
referred from outside sources which provided little or no history information.
Patients were assumed to be at least a member of a high-risk group if the HIV
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antibody test had been ordered by a physician, smce the test is currently not
recommended for low-risk individuals.
Four patients from group 4 were referred by the Central Florida Blood Bank
after testing positive for HIV antibodies during routine blood donations. The other
patient in this group was a nurse who had performed mouth to mouth resuscitation
on a high-risk patient. Because these patients did not belong to any of the highrisk categories, their HIV antibody EIA results were believed to be false positive.
Seven apparently healthy male homosexuals who volunteered to be tested
for HIV antibodies tested positive. After subsequent clinical investigation, four
were placed into Group 2 with a diagnosis of ARC, and three were placed into
Group 3 due to their high-risk status.

Lymphocyte Subset Analysis
Preparation of Mononuclear Cells.

Ten milliliters (mL) of blood was

collected by venipuncture using a vacutainer brand red top tube (no anticoagulant).
One thousand units of sodium heparin were immediately added as anticoagulant and
the blood was mixed well by inversion of the tube 8 - 10 times. The blood was kept
at room temperature before and during transport to our lab.
Mononuclear cells were isolated from the heparinized blood by a modified
density gradient centrifugation technique (86). A suspension medium was prepared
by adding 5% heat inactivated calf serum (Gibco Laboratories) to RPMI-1640 with
25 mM HEPES Buffer (Gibco Laboratories, Madison, WI).

The blood was

separated by centrifugation at 700 X g for 10 minutes at room temperature. The
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buffy coat was transferred to a 15 mL conical centrifuge tube and diluted to 10 mL
with suspension medium. The suspension was then carefully underlaid with 5 mL
of Histopaque-1077 (Sigma Chemical Company, St. Louis, MO) using a long bore
Pasteur pipette. The mixture was centrifuged at 300 X g for 40 minutes at room
temperature.
The mononuclear cells were collected from the interface between the
suspension medium and Histopaque and transferred to a second 15 mL conical
centrifuge tube. The cells were then washed 3 times with 15 mL of suspension
medium by gently resuspending the cell pellet with a Pasteur pipette and centrifuging at 300 X g for 10 minutes.
After the last wash, the cells were resuspended in 1 ·mL of suspension
medium and the mononuclear cell concentration was determined by direct count in
a hemocytometer (87). The concentration of the cell suspension was then adjusted
with suspension medium to 5 X 106 mononuclear cells/mL.
Antibody Reagents. Various combinations of purified antibody or fluorescein

(FITC) or phycoerythrin (PE) conjugated monoclonal reagents were used. The
following reagents were obtained from Ortho Diagnostic Systems (Raritan, NJ):
OKT3, OKT4, OKT8, OKTl 1, OKlal, slg (polyclonal antiserum to surface
immunoglobulin), OKB7, HNKl and goat-anti-mouse IgG FITC-conjugate. The
reagents anti-Leu-2a, anti-Leu-3a, anti-Leu-4, anti-Leu-12, anti-Leu-7, anti-Leu-11a
and goat-anti-mouse IgG (H + L) fluorescein conjugate (second antibody) were
obtained from ~ecton Dickinson Immunocytometry Systems (Mountain View, CA).
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Fluorescent Antibody Staining. Three variations of the staining procedure

were used: direct, indirect and enhanced. The method used was dependent upon
the relative density of the appropriate marker on the surface of the cell and the
corresponding brightness of fluorescence. The direct method was used for subsets
in which the marker was present in a high density on the surface of the cell. This
method utilized a monoclonal antibody directly conjugated with fluorochrome as a
first step reagent and no second step was required.
The indirect and enhanced methods were used for markers present in
decreasing densities which required increasing staining intensities. In the indirect
method, the cells were stained with an unconjugated mouse monoclonal antibody
(first step reagent) followed by a fluorochrome-conjugated goat anti-mouse
immunoglobulin (second step reagent). In the enhanced method, both the first and
second step reagents were fluorochrome-conjugated.
For the first step of all three staining procedures, 200 microliters (µL) of
cell suspension (5 X 106 mononuclear cells per mL) was added to the amount of
monoclonal antibody reagent recommended by the reagent manufacturer.

The

mixtures were incubated in an ice water bath for 30 minutes, with gentle agitation
every 10 minutes. A control containing cells but no antibody was included for each
patient tested.
The cells were then washed twice with 2 mL of cold phosphate buffered
saline (PBS), pH 7.2 - 7.4, after centrifugation at 300 X g for 10 minutes. The final
cell pellets were resuspended in approximately 100 µL of PBS by gentle agitation.
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Cells stained by the direct method were stored in an ice water bath until they were
counted.
The following procedure was used for the indirect and enhanced staining
procedures. Stock goat anti-mouse immunoglobulin was diluted to 15% (v /v) with
suspension medium.

One hundred µL of this solution was added to each cell

suspension and control. After mixing, the tubes were incubated 30 minutes in an
ice water bath and agitated gently every 10 minutes. The cells were washed twice
with 2 mL of cold PBS and centrifugation at 300 X g for 10 minutes. The cells
were finally resuspended in approximately 100 µL of PBS. All cell suspensions were
stored in an ice water bath until they were counted.

Cell Counting.

Wet mounts were prepared by placing a drop of cell

suspension onto an alcohol-cleaned slide and adding a cover slip.

Cells were

counted under oil immersion (1000 X total magnification) using a Bausch & Lomb
Balplan epifluorescence microscope with a 50 watt HBO Mercury lamp, BG-12
exciter filter and 500 nm barrier filter.

For each field of view, the number of

fluorescing cells were counted under epifluorescent illumination. The total number
of lymphocytes in the field were then counted after turning on the halogen base
illuminator. Monocytes and polymorphonuclear cells were distinguished morphologically by size, the presence of a granular cytoplasm and/ or an irregularly shaped
nucleus and these cells were eliminated from the counts. Subsequent fields of view
were counted in a regular pattern across the slide until at least 200 total lymphocytes
had been observed. At least 100 cells from the reagent control were observed to
verify that less than 1% showed nonspecific fluorescence.
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Lymphocyte subset percentages were calculated as the percentage of
fluorescing cells per total number of lymphocytes observed. Absolute white blood
counts (WBC) and differential leukocyte counts were performed by standard manual
methods (88,89). Absolute numbers of lymphocytes per cubic millimeter (mm3) of
blood were calculated by multiplying the WBC (in cells/mm3) by the percentage of
lymphocytes from the differential leukocyte count and by the percentage of the
subset.

HW Antibodies
Antibodies to HIV were detected in serum by enzyme immunoassay (EIA)
using a commercial kit (H1LV-III EIA; Abbott Laboratories, North Chicago, IL).
The assay was performed according to the manufacturer's specifications as described
by the product insert (76).
A cutoff value was determined for each assay using the following equation:
Cutoff Value

= NCx: +

(0.1 x PCx:), where NCx was the mean absorbance given by

a negative control serum assayed in duplicate and PCx: was the mean absorbance of
a positive control serum assayed in triplicate. Results which were below the cutoff
value were called "non-reactive" and considered negative for the presence of
antibodies to HIV. Results above the cutoff value were called "reactive" and all
such samples were retested in duplicate. If the average of the results obtained from
initially reactive samples retested in duplicate was above the cutoff value, the sample
was called "repeatedly reactive" and considered positive for the presence of
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antibodies to HIV.

Samples which were reactive initially, but not repeatedly

reactive, were considered negative for antibodies to HIV.
Since cutoff values are influenced by variations in assay conditions and
reagent lots, they can vary between assays.

Therefore, a ratio of the sample

absorbance to the cutoff absorbance (S/CO value) was calculated and used as a
measure of the degree of positivity. By definition, non-reactive samples had S/CO
values less than one, while reactive samples had S/CO values greater than or equal
to one. S/CO values between 1.0 and 3.0, inclusive, were denoted as "borderline"
and those greater than 3.0 were considered "strong positive".

Other Laboratory Tests

Serum levels of immunoglobulins IgG, lgA and IgM were determined by a
radial immunodiffusion (RID) method using a commercial kit (Quantiplate
Immunoglobulin Test Kit; Kallestad Laboratories, Austin, Texas). The assays were
performed according to the kit manufacturer's specifications as described in the
package insert (90). The results were read and calculated by the timed method
described by Fahey and McKelvey (91) and reported in units of milligrams per
deciliter of serum (mg/dL).
Serum levels of Complement C3 and C4 were determined by an RID method
using commercial kits (Endoplate Test Kits; Kallestad Laboratories). The assays
were performed according to the kit manufacturer's specifications as described in
the package insert (92). The results were read and calculated by the Mancini
endpoint method (93) and reported in units of mg/dL.
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Serum levels of B2 -microglobulin were determined by a competitive binding
radioimmunoassay (RIA) method using a commercial kit (Phadebas B2 -Micro Test;
Pharmacia Diagnostics, Uppsala, Sweden). The assays were performed according to
the kit manufacturer's specifications as described in the package insert (74 ). Results
were reported in units of micrograms per liter of serum (µg/L).
Levels of circulating immune complexes were measured in serum by an
ELISA method using a commercial kit (Cordia IC 65 Test Kit; Cordis Laboratories,
Miami, Florida). The assay detected IgG immune complexes which were bound to
Complement Clq. The assays were performed according to the kit manufacturer's
specifications as described in the package insert (94 ). Results were reported in units
of microgram equivalents of aggregated human IgG per rnL of serum (µg eq
HAlgG/mL).

Statistical Met hods
Kruskal-Wallis H (KWH) Test. The KWH test was used to determine if the
probability distributions of patient results for a particular assay were significantly
different for any of the six patient groups. Such a nonparametric technique was
necessary because the sample distributions were often non-symmetrical and their
variances were not equal.

The KWH test requires no assumptions about the

population probability distributions; only that the six patient groups are random and
independent, and that there are five or more measurements in each sample (99).
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Results for each type of assay were combined for the patients in all patient
groups and ranked from lowest to highest. Multiple results for a single patient were
averaged before being included in the ranks. Values which were equal (ties) were
assigned ranks equal to the average of the ranks for the values which were tied.
The H statistic was then calculated according to the formula given in Figure 1. Data
from patient groups with fewer than five samples were not included in the statistical
analyses.
The value of the H statistic was compared with the chi square value for the
95 % confidence level using N - 1 degrees of freedom, where N equals the number
of patient groups compared. If the H statistic was larger, the null hypothesis, that
there were no significant differences between the probability distributions for the
patient groups compared, was rejected.

The results were therefore considered

significantly (p < .05) different for at least one of the patient groups and multiple
comparison analysis was used to determine between which groups the differences
existed.

Multiple Comparison Analysis. The multiple comparison procedure was used
to compare individual pairs of patient groups after the KWH test had determined
that the assay results were significantly different for at least one of the six groups.
The probability of making the error of declaring a significant difference
between a pair of samples when the difference does not actually exist increases as
the number of comparisons increases. The multiple corµparison procedure contains
an adjustment for the increased probability of making a statistical error due to a
large number of comparisons (96).
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Figure 1. Statistical Methods.
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The multiple comparison procedure was performed for all possible pairs of
patients groups which had five or more samples. An "experimentwise" error rate (a)
of 0.15 was used. If the equation in Figure 1 was found to be false, the difference
in results between the two groups was declared significant at the a level. The sign
of the difference between the mean ranks indicated the direction of the difference.

RESULTS

Patient Groups

Demographics for all patient groups are summarized in Table 1. The KWH
test indicated that the differences in ages between patient groups were statistically
significant (p < .05). Multiple comparison analysis, however, did not detect any
differences in age between individual pairs of these groups.

Lymphocyte Subsets

Lymphocyte subset analyses on normal individuals are summarized in Table
2. These results were obtained using a variety of monoclonal reagents for each
subset. The differences in percentages obtained using different reagents for the
same subset were not statistically significant (p < .05), according to the KWH test.
Therefore, the normal range of percentages for each subset were determined by
calculating the mean ± 1 standard deviation of the percentages obtained from all
antibodies used.
Total leukocyte and total lymphocyte absolute numbers for all patient groups
are summarized in Table 3. All patient groups had mean total leukocyte and total
lymphocyte numbers within the normal range. The KWH test indicated that there
were statistically significant (p < .05) differences in total leukocyte absolute numbers
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TABLE I
PATIENT DEMOGRAPHICS

1

PATIENT
2
3

GROUP
4
5

6

NUMBER OF PATIENTS

14

21

147

4

122

41

SEX
Male
Female
Unlrnown

11
2
1

20
1
0

116
26
5

3
1
0

56
65
1

18
23
0

AGE (Mean in years)

34.5

28.6

36.3

54.3

36.2

31.2

MEMBERS OF HIGH-RISK
Male homosexuals
IV Drug Users
Blood Recipients
Sexual Partners of HRI
Infants born to HRI

GROUPS
5
19
0
1
0
0
0
0
0
1

5
0
0
4
5

0
0
0
0
0

1
0
0
0
0

6
0
0
0
0

SOURCES OF REFERRAL
Hospital
Private Physician
Blood Bank
Health Department
Volunteer

9
4
0
1
0

2
10
0
5
4

103
37
1
3
3

0
1
3
0
0

16
106
0
0
0

0
0
0
0
41

HRI = High Risk Individual. Patient classification: patients with AIDS (Group
1), patients with ARC or LAS (Group 2), other patients with possible AIDSrelated conditions (Group 3), patients with a possible false-positive HIV antibody
test (Group 4), patients with other immunologic disorders not related to AIDS
(Group 5), and healthy individuals (Group 6).
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TABLE 2
LYMPHOCYTE SUBSET PERCENTAGES

IN NORMAL INDMDUALS

MONOCLONAL
ANTIBODY

N

OKT3
OKTll
Anti-Leu 4

16
16
101

OKial
OKB7
slg
Anti-Leu 12

7
24
12
43

OKT4
Anti-Leu 3a

17
117

OKT8
Anti-Leu 2a

17
117

HNKl
Anti-Leu 7
Anti-Leu 11

13
41
57

NORMAL RANGE:

TOTAL
H/I
NK
S/C
T CELLS B CELLS T CELLS T CELLS CELLS
62-74%
61-75%
61-77%
10-24%
7-14%
9-15%
6-16%
40-53%
39-55%
19-30%
17-29%
4-13%
4-11%
4-13%
61-76%

7-15%

8-55%

7-29%

4-12%

Results are given as the mean ± 1 standard deviation for N number of tests. slg
is a polyclonal antiserum to surface immunoglobulin. H/I = Helper/Inducer, S/C
= Suppressor/ Cytotoxic.

between patient groups.

Multiple comparison analysis indicated that the total

leukocyte numbers from patients in group 2 were lower than those from patients in
groups 3 and 5. The KWH test indicated that there were not statistically significant
(p < .05) differences in total lymphocyte absolute numbers between patient groups.
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TABLE 3
TOTAL LEUKOCYTES
AND TOTAL LYMPHOCYTES

1

PATIENT
2
3

GROUP
4
5

TOTAL LEUKOCYTES (Normal range = 4500 - 10100 cells/mm3)
Group Mean
6522
5833
8180
7100
8037
% Below Normal
17
27
7
50
5
% Above Normal
O
O
21
O
11
No. of Patients Tested
6
15
44
2
63
TOTAL LYMPHOCYTES (Normal range = 1500 - 4000 cells/mm3)
Group Mean
2074
2644
2610
2124
2637
% Below Normal
33
8
20
0
12
% Above Normal
O
15
17
0
10
No. of Patients Tested
3
13
41
2
50

6

8041

o

13
16
3379
0
8
12

Patient classification: patients with AIDS (Group 1), patients with ARC or LAS
(Group 2), other patients with possible AIDS-related conditions (Group 3),
patients with a possible false-positive HIV antibody test (Group 4), patients with
other immunologic disorders not related to AIDS (Group 5), and healthy
individuals (Group 6).

Helper/inducer T cell percentages and absolute numbers for all patient
groups are summarized in Table 4. Patient groups 1, 2 and 3 had mean helper/inducer T cell percentages below the normal range. The KWH test indicated that
there were statistically significant (p < .05) differences in helper /inducer T cell
percentages between patient groups. Multiple comparison analysis indicated that the
helper/inducer T cell percentages from patients in groups 1, 2 and 3 were lower than
those from patients in groups 5 and 6, and those from patients in group 1 were lower
than those from patients in group 3.
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TABLE 4
HELPER/INDUCER T-CELLS

1

PATIENT
2
3

GROUP
4
5

PERCENT OF LYMPHOCYTES (Normal range = 38 - 55%)
Group Mean
17
33
35
50
% Below Normal
92
63
57
O
% Above Normal
O
O
8
50
No. of Patients Tested
13
16
74
2

6

45
23
17
108

47
11
17
18

ABSOLUTE NUMBERS (Normal range = 1154 - 1842 cells/mm3)
Group Mean
471
887
917
1074
1324
% Below Normal
67
69
66
50
48
% Above Normal
O
8
12
0
14
No. of Patients Tested
3
13
41
2
50

1497
17
17
12

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or LAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive HIV antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

Patient groups 1, 2, 3 and 4 bad mean helper /inducer T cell absolute numbers
below the normal range.

The KWH test indicated that there were statistically

significant (p < .05) differences in helper /inducer T cell absolute numbers between
patient groups.

Multiple comparison analysis indicated that the helper/inducer

T cell absolute numbers from patients in groups 2 and 3 were lower than those from
patients in group 6, and those from patients in group 3_were lower than those from
patients in group 5.
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Suppressor/ cytotoxic T cell percentages and absolute numbers for all patient
groups are summarized in Table 5. Patient groups 1, 2 and 3 had mean suppressor/cytotoxic T cell percentages above the normal range. The KWH test indicated that
there were statistically significant (p < .05) differences in suppressor/ cytotoxic T cell
percentages between patient groups. Multiple comparison analysis indicated that the
suppressor/ cytotoxic T cell percentages from patients in groups 1, 2 and 3 were
higher than those from patients in groups 5 and 6, and those from patients in group
2 were higher than those from patients in group 3.
All patient groups had mean suppressor/ cytotoxic T cell absolute numbers
within the normal range. The KWH test indicated that there were statistically
significant (p < .05) differences in suppressor/ cytotoxic T cell absolute numbers
between patient groups. Multiple comparison analysis indicated that the suppressor/ cytotoxic T cell absolute numbers from patients in groups 2 and 3 were higher
than those from patients in group 5, and those from patients in group 5 were lower
than those from patients in group 6.
Helper to suppressor ratios for all patient groups are represented graphically
in Figure 2. Patient groups 1, 2 and 3 had mean helper to suppressor ratios below
the normal range. The KWH test indicated that there were statistically significant
(p < .05) differences between helper to suppressor ratios between patients groups.
Multiple comparison analysis indicated that the helper to suppressor ratios from
patients in groups 1, 2 and 3 were lower than those from patients in groups 5 and

6.
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TABLES
SUPPRESSOR/CYTOTOXIC T-CELLS

1

PATIENT
2
3

GROUP
4
5

PERCENT OF LYMPHOCYTES (Normal range = 17 - 29%)
Group Mean
40
44
33
27
% Below Normal
8
0
9
O
% Above Normal
85
94
55
50
No. of Patients Tested
13
16
75
2

6

21
30
10
108

24
6
6
18

ABSOLUTE NUMBERS (Normal range = 440 - 1194 cells/mm3 )
Group Mean
1111
1159
898
561
545
% Below Normal
33
0
27
0
46
% Above Normal
67
39
22
0
6
No. of Patients Tested
3
13
41
2
50

816
8
8
12

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or LAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive HN antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

Total T cell percentages and absolute numbers for all patient groups are
summarized in Table 6. Patient group 1 had a mean total T cell percentage below
the normal range. The KWH test indicated that there were statistically significant
(p < .05) differences in total T cell percentages between patient groups. Multiple
comparison analysis indicated that the total T cell percentages from patients in
groups 1 and 5 were lower than those from patients in group 6, those from patients
in group 1 were lower than those from patients in group 2, and those from patients
in group 2 were higher than those from patients in groups 3 and 5.
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Figure 2. Helper to Suppressor Ratios.
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TABLE 6
TOTAL T-CELLS

1

PATIENT
2
3

GROUP
4
5

PERCENT OF LYMPHOCYTES (Normal range = 61 - 76%)
Group Mean
55
74
65
66
% Below Normal
62
13
32
50
% Above Normal
8
56
13
50
No. of Patients Tested
13
16
63
2

6

64
34
13
111

70
6
22
18

ABSOLUTE NUMBERS (Normal range = 1794 - 2792 cells/mm3)
Group Mean
1489
1970
1768
1406
1774
% Below Normal
33
39
54
100
58
% Above Normal
O
8
15
0
8
No. of Patients Tested
3
13
41
2
50

2291
17
17
12

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or lAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive HIV antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

Patient groups 1, 3, 4 and 5 had mean total T cell absolute numbers below
the normal range. The KWH test indicated that there were statistically significant
(p < .05) differences in total T cell absolute numbers between patient groups.
Multiple comparison analysis indicated that the total T cell absolute numbers from
patients in groups 3 and 5 were lower than those from patients in group 6.
B cell percentages and absolute numbers for all patient groups .are
summarized in Table 7. Patient groups 1 and 4 had mean B cell percentages above
the normal range. The KWH test indicated that there were statistically significant
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TABLE 7
B-CELLS

PATIENT
1

2

3

GROUP

4

5

6

PERCENT OF LYMPHOCYTES (Normal range = 7 - 15%)
Group Mean
15
9
12
16
% Below Normal
O
44
19
O
% Above Normal
39
25
21
50
No. of Patients Tested
13
16
63
2

12
17
23
108

10
17
O
18

ABSOLUTE NUMBERS (Normal range = 245 - 429 cells/mm3)
Group Mean
372
235
305
347
% Below Normal
33
62
59
50
% Above Normal
67
15
22
50
No. of Patients Tested
3
13
41
2

318
47
23
47

337
17
17
12

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or LAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive HIV antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

(p < .05) differences in B cell percentages between patient groups.

Multiple

comparison analysis, however, did not detect any differences in B cell percentages
between individual pairs of patient groups.
Patient group 2 had a mean B cell absolute number below the normal range.
The KWH test indicated that there were statistically significant (p < .05) differences
in B cell absolute numbers between patient groups. ~ultiple comparison analysis,
however, did not detect any differences in B cell absolute numbers between
individual pairs of patient groups.
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Natural Killer cell percentages and absolute numbers for all patient groups
are summarized in Table 8. Patient groups 1 and 3 had mean natural killer cell
percentages above the normal range. The KWH test indicated that there were
statistically significant (p < .05) differences in natural killer cell percentages between
patient groups. Multiple comparison analysis indicated that the natural killer cell
percentages from patients in group 1 were higher than those from patients in groups
5 and 6.
All patient groups had mean natural killer cell absolute numbers within the
normal range. The KWH test indicated that there were statistically significant (p <
.05) differences in natural killer cell absolute numbers between patient groups.
Multiple comparison analysis, however, did not detect any differences in natural
killer cell absolute numbers between individual pairs of patient groups.

HW Antibodies
Results of HIV antibody tests from patients in all patient groups are
summarized in Table 9. The results were classified according to their S/CO values
into three categories: negative (S/CO less than 1), borderline (S/CO between 1 and
3, inclusive), and strong positive (S/CO greater than 3).
Some patients were retested periodically and the mean S/CO values for each
patient in each category were used to compile the table. Of the four patients in
group 4, two had both negative and borderline results at different times. Therefore,
the numbers of patients with negative and borderline results add up to more than
the total number of patients tested from this group.
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TABLE 8
NATURAL KILLER CELLS

1

PATIENT
2
3

GROUP
4
5

PERCENT OF LYMPHOCYTES (Normal range = 4 - 12%)
Group Mean
17
12
13
12
% Below Normal
0
6
4
0
% Above Normal
75
44
44
50
No. of Patients Tested
12
16
57
2

11
13
35

88

ABSOLUTE NUMBERS (Normal range = 0 - 1013 cells/mm3)
Group Mean
341
364
345
244
265
% Below Normal
% Above Normal
0
8
3
0
0
No. of Patients Tested
3
13
40
2
46

6

9
6
17
18
404

8
12

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or LAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive HIV antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

The KWH test indicated that there were not statistically significant (p < .05)
differences in strong positive S/CO values between patients from groups 1, 2 and 3,
and there were not statistically significant (p < .05) differences in negative S/CO
values between patients from groups 3, 5 and 6.
The changes in HIV antibody test results in a patient from group 4 are shown
in Figure 3. On day zero, the patient was tested by the Central Florida Blood Bank
during a routine blood donation. The results of these tests were repeatedly reactive
with a mean S/ CO value of approximately 2.0. The patient was referred to our
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TABLE 9
HIV ANTIBODIES

1
NEGATIVE (S/CO < 1.0)
Number of Patients
Mean S / CO Value

1

PATIENT
2
3

GROUP
4
5

6

0

85
0.31

4
0.65

29
0.33

32
0.31

3.0)
0

0

6
1.48

3
1.23

0

0

STRONG POSITIVE (S/CO > 3.0)
Number of Patients
7
16.8
Mean S / CO Value

19
18.9

25
14.2

0

0

0

19

114

5

29

32

BORDERLINE (1.0
Number of Patients
Mean S/CO Value

$

No. of Patients Tested

S/CO

0.60
$

8

See the text for an explanation for why the numbers of patients in each category
do not equal the total number of patients tested. Patient classification: patients
with AIDS (Group 1), patients with ARC or LAS (Group 2), other patients with
possible AIDS-related conditions (Group 3), patients with a possible false-positive
HIV antibody test (Group 4), patients with other immunologic disorders not
related to AIDS (Group 5), and healthy individuals (Group 6).

facility and re-tested 14 and 20 days later. The results of these tests were repeatedly
reactive with mean S/CO values of 1.3 and 1.2, respectively. Seventy-two days after
the initial test, the patient's serum was found to be non-reactive, with an S/CO value
of 0.8.
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Figure 3. HIV Antibodies in a Patient Without Risk Factors for AIDS.

Other Laboratory Tests
Serum im.munoglobulin levels for all patient groups are summarized in Table
10. Patient groups 1 and 2 had mean IgG values above the normal range. The
KWH test indicated that there were statistically significant (p < .05) differences in
IgG levels between patient groups. Multiple comparison analysis indicated that the
IgG levels from patients in groups 1, 2 and 3 were higher than those from patients
in group 5, and those from patients in group 2 were also higher than those from
patients in groups 3 and 6.
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TABLE 10
SERUM IMMUNOGLOBUIN LEVELS

1

PATIENT
2
3

GROUP
4
5

6

IMMUNOGLOBULIN G (Normal range: 812-1293 mg/dL)
Group Mean (mg/dL)
1688
1880
1290
1175
% Below Normal
0
0
12
0
% Above Normal
83
83
45
33
No. of Patients Tested
6
13
49
3

992
19
6
16

1185
5
30
20

IMMUNOGLOBULIN A (Normal range: 68-378 mg/dL)
Group Mean (mg/dL)
350
321
244
273
% Below Normal
0
0
7
0
% Above Normal
50
29
22
O
No. of Patients Tested
6
14
45
3

161
6
6
16

211
11
11
19

IMMUNOGLOBULIN M (Normal range: 54-258 mg/dL)
Group Mean (mg/dL)
207
180
166
157
% Below Normal
O
O
7
0
% Above Normal
17
17
16
0
No. of Patients Tested
6
12
44
3

208
0
20
15

201
5
20
20

Group mean values outside of the normal ranges are shown in bold type. Patient
classification: patients with AIDS (Group 1), patients with ARC or LAS (Group
2), other patients with possible AIDS-related conditions (Group 3), patients with
a possible false-positive IIlV antibody test (Group 4), patients with other
immunologic disorders not related to AIDS (Group 5), and healthy individuals
(Group 6).

All patient groups had mean IgA values within the normal range. The KWH

test indicated that there were statistically significant (p < .05) differences in IgA
levels between patient groups. Multiple comparison ~alysis indicated that the IgA
levels from patients in groups 1, 2 and 3 were higher than those from patients in
group 5.
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All patient groups had mean IgM values within the normal range. The KWH
test indicated that there were statistically significant (p < .05) differences in IgM
levels between patient groups.

Multiple comparison analysis, however, did not

detect any differences in serum IgM levels between individual pairs of patient
groups.
Serum Complement levels for all patient groups are summarized in Table 11.
All patient groups had mean C3 and C4 values within the normal ranges. The KWH
test indicated that the differences in Complement C3 and C4 levels between patient
groups were not statistically significant (p < .05).
Serum 8 2-microglobulin levels for all patient groups are summarized in Table
12. Patient groups 1, 2 and 3 had mean serum 8 2-microglobulin values above the
normal range. The KWH test indicated that there were statistically significant (p <
.05) differences in 8 2-microglobulin levels between patient groups.

Multiple

comparison analysis indicated that the serum 8 2-microglobulin levels from patients
in groups 1 and 3 were higher than those from patients in groups 5 and 6.
Levels of circulating immune complexes for all patient groups are summarized
in Table 13. Patient groups 1 and 2 had mean immune complex levels above the
normal range. The KWH test indicated that there were statistically significant (p
< .05) differences in the levels of circulating immune complexes between patient
groups. Multiple comparison analysis showed that the levels of circulating immune
complexes from patients in group 1 were higher than those from patients in group

3.
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TABLEU
SERUM COMPLEMENT LEVELS

1

PATIENT
2
3

COMPLEMENT C3 (Normal range: 80-180 mg/dL)
Group Mean (mg/dL)
112
136
134
% Below Normal
17
0
5
% Above Normal
O
O
13
No. of Patients Tested
6
8
56
COMPLEMENT C4 (Normal
Group Mean (mg/dL)
% Below Normal
% Above Normal
No. of Patients Tested

range: 15-45 mg/dL)
28
30
30
33
0
4
17
0
9
6
8
56

GROUP
4
5

6

171
0
33
3

141

16

119
5
0
22

33
0

28
6

25
9

0
3

0

0

16

22

0
0

Patient classification: patients with AIDS (Group 1), patients with ARC or LAS
(Group 2), other patients with possible AIDS-related conditions (Group 3),
patients with a possible false-positive HIV antibody test (Group 4), patients with
other immunologic disorders not related to AIDS (Group 5), and healthy
individuals (Group 6).
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TABLE 12
SERUM 6 2-MICROGWBULIN LEVELS

1
Group Mean (µg/L)
% Below Normal
% Above Normal
No. of Patients Tested

PATIENT

GROUP

2

3

4

5

6

8232

3306

4569

0
100
5

0
87
15

1685
0
30
10

1449

0
100
1

1650
0
0
1

13

0
8

The normal range is 1130 - 2000 µg/L. Values outside of the normal range are
shown in bold type. Patient classification: patients with AIDS (Group 1), patients
with ARC or LAS (Group 2), other patients with possible AIDS-related conditions
(Group 3), patients with a possible false-positive HIV antibody test (Group 4),
patients with other immunologic disorders not related to AIDS (Group 5), and
healthy individuals (Group 6).

TABLE13
CIRCULATING IMMUNE COMPLEXES

1
Group Mean (µg eq/mL)
% Above Normal
No. of Patients Tested

21
33
6

PATIENT
2
3

80
100
1

GROUP
4
5

6

12
25

0

6

7

8

8

11

13

9

The normal range is > 12 µg eq/mL. Values outside of the normal range are
shown in bold type. Patient classification: patients with AIDS (Group 1), pa!i~nts
with ARC or LAS (Group 2), other patients with possible AIDS-related cond1t10ns
(Group 3), patients with a possible false-positive HIV antibody test (Group 4),
patients with other immunologic disorders not related to AIDS (Group 5), and
healthy individuals (Group 6).

DISCUSSION

Lymphocyte subset results in this paper are expressed in two ways: 1) as a
percentage of the total number of lymphocytes and 2) as the number of cells per
mm

3

of blood.

Lymphocyte subset results expressed as percentages can be

considered "relative" because they represent the proportion of a cell population in
relation to the total number of lymphocytes. Relative numbers of a cell subset are
therefore influenced by the numbers of cells in the other subsets. For example, a
decrease in the number of helper /inducer T cells will cause an increase in the
percentage of suppressor/ cytotoxic T cells, even if the number of suppressor/cytotoxic T cells remains the same.
Absolute numbers of a cell subset are not influenced by the numbers of
cells in the other subsets. Therefore, the terms "relative" and "absolute" will be used
to refer to changes in lymphocyte subset results expressed as a percentage of the
total lymphocytes and as the number of cells per mm3, respectively.
Relative and absolute reductions of helper/inducer T cells were observed in
all three AIDS-related patient groups (groups 1,2 and 3). Similar findings have been
reported elsewhere (97,98). These findings are consistent with the selective tropism
and cytotoxicity of the HIV virus for cells of the helper/inducer phenotype (15).
The CD4 marker used to identify helper /inducer T cells in vitro has been shown to
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be the receptor for the HIV virus (16). The loss of helper/inducer T cells that
occurs as a result of the destruction of infected cells is believed to be the major
cause of immune deficiency in AIDS (99).
Reductions in helper/inducer T cells were greater and more frequent in
patients with AIDS than in those with ARC. Such findings are consistent with the
observation that patients with AIDS have greater degrees of immune deficiency than
those with ARC (100).
Relative and absolute increases in suppressor/ cytotoxic T cells were observed
in all AIDS-related patient groups. Similar findings have been reported elsewhere
(101).
Relative increases in suppressor/ cytotoxic T cells are expected due to the
observed reductions in helper /inducer T cells. Absolute increases in suppressor/cytotoxic T cells might be due to the clonal expansion of cytotoxic T cells which have
been activated to fight secondary conditions. Other investigators have reported an
augmentation of suppressor functions in AIDS and ARC patients (9).
Apparent increases in suppressor/ cytotoxic T cells may also be caused by
increases in subpopulations of NK cells which bear the CD8 marker. Two-color flow
cytometric analysis has shown that some Leu-11-bearing cytotoxic NK cells express
low density CD8 (69) and some Leu-7-bearing cells express high density CDS (70).
The latter cells, which do not possess cytotoxic NK activity (70), have been found to
be elevated in many patients with AIDS and ARC ar:id in some healthy high-risk
individuals (104,105).
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Significant reductions of helper to suppressor ratios were observed in all three
AJDS-related patient groups. These reductions were the greatest in patients with
AIDS and they were the least in group 3. Similar results have been reported by
other investigators (102). The evidence discussed above suggests that the observed
reductions in helper to suppressor ratios were due primarily to reductions in
helper/inducer T cells and secondarily to increases in suppressor/cytotoxic T cells.
Low helper to suppressor ratios were also observed in a few apparently
healthy individuals from group 6. Therefore, transitory reductions of the helper to
suppressor ratio may be present in otherwise healthy individuals, possibly due to
mild or subclinical infections.
Reduced helper to suppressor ratios have also been reported in apparently
healthy male homosexuals (98,106,107) and hemophiliacs (94).

Many of these

reduced ratios were found to be the result of absolute increases in suppressor/cytotoxic T cells without absolute decreases in helper/inducer T cells (98,107,108).
Significant relative and absolute reductions of total T cells were observed in
patients with AJDS. Relative increases in total T cells were observed in patients
with ARC, although absolute increases above the normal range were not evident.
The observed decreases in total T cells in patients with AJDS can be
explained by greater reductions in helper/inducer T cells and smaller increases in
suppressor/ cytotoxic T cells in the AIDS group. The observed increases in total
T cells in patients with ARC may be due to smaller reductions in helper/inducer
T cells and greater increases in suppressor/cytotoxic T cells in the ARC group.
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Although statistically significant changes in B cells were not observed in any
of the patient groups, relative and absolute increases in B cells were observed in a
large proportion of patients with AIDS. In contrast, relative and absolute decreases
in B cells were observed in a large proportion of patients with ARC.
Other patients with AIDS have been found to have increases in B cells
secreting polyclonal immunoglobulin (109,110). It has been suggested that these
cells are responsible for the observed increases in serum immunoglobulin, immune
complexes, and autoantibodies.

Other investigators have suggested that B cell

increases in some AIDS patients might be related to co-infection with Epstein Barr
Virus (EBY), which has been shown to cause polyclonal stimulation of B cells into
antibody-secreting cells ( 111 ).
Significant relative elevations of NK cells were observed in patients with
AIDS, however, absolute increases were not observed. This observation may be
explained by the observed loss of T cells which increases only the relative numbers
of NK cells.
Other investigators have reported that AIDS patients have little or no NK
functional activity, as determined by their inability to release soluble NK cytotoxic
factors (91). More recent studies have shown that although some AIDS patients
have reduced NK activity, such reductions might be only transient (112).
Lymphocyte subsets were enumerated in two patients from group 4 who had
positive HIV antibody tests, although they were not believed to be at risk for AIDS.
Overall, these patients had relatively normal lymphocyte subset panels, including low
to normal absolute numbers of helper/inducer T cells and normal helper to
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suppressor ratios. Lymphocyte subset analysis in these patients, therefore, supported
the -suspicion that the HIV antibody test was false-positive.
All patients with ARC and all but one patient with AIDS were positive for
antibodies to HIV by the EIA methodology. The AIDS patient who tested negative
was very ill, with extreme leukopenia, lymphopenia and a low helper to suppressor
ratio. Similar results have been reported in other AIDS patients who apparently
cannot make antibody due to a severe degree of immune deficiency (113).
Since the S/CO values of strong positive EIA tests were not significantly
different between the three AIDS-related patient groups, there is no evidence of a
relationship between the stage of the disease and the degree of positivity for the
HIV antibody EIA.
Borderline results for the illV antibody EIA occurred occasionally in patients
and controls from all groups, but they were usually negative upon repeat testing.
Such results were probably due to experimental error.
The five patients in group 4 bad positive results for the EIA for antibodies
to HIV performed by other laboratories. Upon repeat testing in our laboratory, two
of these patients were negative and three were borderline positive. Two of the
latter patients gradually became negative upon further repeat testing over periods
of a few months, while the other patient currently remains borderline positive.
Six high-risk patients from group 3 also had borderline positive results for the
HIV antibody EIA. Since these patients have not been subsequently followed, it is
unclear whether some of these patients may also be false-positive for illV
antibodies.
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False-positive HIV antibody EIA results might be caused by contaminants of
the viral antigen used in the assay (114). The antigen is prepared in tissue culture
using special leukemic cell lines (15). Since the viral envelope is derived from the
host cell membrane, the envelope also contains host membrane glycoproteins,
including HLA and other alloantigens. Some of these alloantigens might not be
removed during the purification of the virus. Some investigators have reported that
some patients with apparent false-positive lilV antibody tests have antibodies to
cellular material from the H9 cell line commonly used to grow the virus (114,115).
The presence of autoantibodies (anti-nuclear, anti-mitochondrial and anti-T cell
antigens) has also been highly correlated with false positive HIV EIA's (114).
Autoantibodies are directed against certain components of the cell in general,
including those components of the patient's own cells. Patients with autoantibodies
might also react with cellular contaminants of the viral antigen used in the assay for
HIV antibodies.
As recommended by the U.S. Public Health Service (116), the Western blot

assay is commonly used as a confirmatory test for lilV antibodies in patients with
a positive EIA. In this method, the viral antigens are separated electrophoretically
in denaturing polyacrylamide gels (117). The separated bands of antigen are then
transferred to nitrocellulose paper by a protein blotting technique. Strips of this
paper are incubated with patient sera. If present, antibodies to specific viral antigens
are visualized by EIA, utilizing an antiserum of horseradish peroxidase-conjugated
anti-human iD?IDunoglobulin.

Individual viral antigens are identified by their

electrophoretic mobility in relation to standards of known molecular weight.
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Evidence of the presence of antibodies bound to either or both of the bands with
molecular weights of 24,000 (p24) and 41,000 (p41) is considered a positive test for
the presence of HIV antibodies (116).
Theoretically, the Western blot assay should provide greater specificity than
the EIA because it detects antibodies to specific viral proteins, rather than to the
virus as a whole. However, cellular material from crude viral antigen preparations
have also been found to interfere with the Western blot assay (114). Furthermore,
the Western blot assay is expensive, labor intensive, difficult to standardize and the
results are subjective (118).
Experience in our clinic has suggested that the confirmation of high-positive
EIA tests by Western blot is not necessary.

In cases where the EIA result is

borderline, the Western blot assay might also be of little benefit. The patient
referred to in Figure 3 had Western blot results which were interpreted as
"indeterminant". Therefore, we do not routinely use the Western blot for confirmation of positive EIA results in our laboratory.
Recent improvements in the method of preparing the viral antigen used in in

vitro tests will hopefully improve the specificity of both the EIA and Western blot
assays. In the future, viral antigen prepared by DNA recombinant technology might
also reduce the number of false-positives. EIA tests which are more specific for the
envelope and core proteins might also be available in the United States in the near
future.
The sensitivity of a clinical assay can be defined as the percentage of positive
tests when testing a population in which the prevalence of the analyte is 100%. The
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specificity of an assay can be defined as the percentage of negative tests when testing
a population in which the prevalence of the analyte is 0% (76).
For any assay for antibodies to HIV, the proportion of positives which are
false positive is determined not only by the sensitivity and specificity of the assay,
but also by the prevalence of HIV antibodies in the population being tested (76).
When the HIV antibody EIA is used to screen low-risk populations in which the
prevalence of HIV antibodies is assumed to be low, a significant proportion of the
positives are expected to be false (77,118). Because of the social and mental impact
of a positive test, assays for HIV antibodies should be used with extreme caution in
low-risk populations.
Our findings that serum levels of IgG are increased in patients with AIDS
and related conditions more often than those of IgA and IgM are consistent with
other reports in the literature (97,98). Other investigators have demonstrated that
the observed increases of serum immunoglobulins in these patients are polyclonal
(119). Some researchers have suggested that these increases might be related to
stimulation of B cells by EBV and other viruses (111).
Due to the large incidence of secondary infections and the presence of
complement-binding immune complexes in AIDS and ARC patients, changes in the
levels of serum complement components might be expected. The absence of such
changes in this study might be a demonstration of the liver's ability to regulate and
normalize the levels of complement components in the peripheral blood. Perhaps
an assay for activated complement components might be better able to detect the
activation of complement in patients with AIDS and ARC.
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The observation of dramatic increases in the levels of serum B2-microglobulin
might be attributed to several processes, including liberation of these proteins from
dying cells and increased production due to the synthesis of new cells and
immunoglobulin molecules. Similar results have been reported by other investigators
(98,99, 100).
Although the mean B2-microglobulin level appeared higher for group 1 than
for groups 2 and 3, the differences were not statistically significant (p < .05). Other
investigators have also found that the B2-microglobulin levels were not significantly
different between patients with AIDS and those with ARC (98).
Other investigators have reported the presence of circulating immune
complexes in patients with AIDS-related diseases (120). The higher prevalence of
circulating immune complexes observed in the ARC group may be another indicator
of a less severely suppressed immune system in these patients.
In summary, AIDS-related patients overall showed significant (p < .05)
relative and absolute decreases in helper/inducer T cells, and relative and absolute
increases in suppressor/ cytotoxic T cells, resulting in dramatic decreases in helper
to suppressor ratios. Relative decreases in total T cells and increases in B cells and
natural killer (NK) cells were also observed in some AIDS-related patients. Four
patients not at risk for AIDS had borderline and possibly false positive HIV antibody
results. Antibody levels in one of these patients gradually changed to negative after
a period of a few weeks. AIDS-related patients overall were also found to have
significant (p < .05) increases in serum levels of immunoglobulins, B2-microglobulin,
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and circulating immune complexes.

Significant changes m serum levels of

Complement C3 and C4 were not observed.
Determinations of lymphocyte subpopulations and antibodies to HIV were
found to be the most valuable in the laboratory evaluation of patients with AIDSrelated diseases. Serum levels of 8 2-microglobulin, immunoglobulins (especially
IgG), and Clq immune complexes were also abnormal in many AIDS-related
patients. Serum levels of Complement C3 and C4 did not appear to be of diagnostic
or prognostic value.
When evaluating helper to suppressor ratios, it is important to determine
whether reductions were caused by decreases in helper/inducer T cells and/or
increases in suppressor/cytotoxic T cells. It is also important to look at absolute
numbers of cells, in addition to relative percentages.
Although the HIV antibody test appears to be highly sensitive when used on
high-risk individuals, considering the impact of a positive test, specificity of the assay
is a problem for low-risk populations. The use of this test to screen low-risk
populations is inadvisable until improvements in specificity and confirmatory tests
are made.
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